HEREDITARY ANGIOEDEMA
Clinical trials for HEREDITARY ANGIOEDEMA explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY ANGIOEDEMA trials appear
Sign up with your email to follow new studies for HEREDITARY ANGIOEDEMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill could stop debilitating HAE attacks in their tracks
Disease control CompletedThis study tested an oral medication, BCX4161, to prevent sudden swelling attacks in people with hereditary angioedema (HAE), a rare genetic condition. About 110 adults with HAE type I or II took either a low dose, high dose, or placebo daily for 12 weeks. Researchers tracked how…
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE2, PHASE3 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 07:05 UTC
-
New HAE drug shows promise in Long-Term safety trial
Disease control CompletedThis study looked at the long-term safety and effectiveness of a drug called donidalorsen for people with hereditary angioedema (HAE), a condition that causes sudden, severe swelling. Twenty adults who had already completed an earlier study received the drug as a shot under the s…
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE2 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 07:04 UTC
-
New HAE drug shows promise in early trial
Disease control CompletedThis study tested a new drug, navenibart, in 29 people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. Participants received one or two doses of the drug to see if it is safe and helps reduce swelling attacks. The goal is to find a better way t…
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE1, PHASE2 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 06:51 UTC
-
New pill shows promise for kids with rare swelling disorder
Disease control CompletedThis study tested an oral drug called sebetralstat in 36 children aged 2 to 11 with hereditary angioedema (HAE) Types I or II, a condition causing sudden painful swelling. The main goal was to check safety and how the body processes the drug. Researchers also measured how quickly…
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE3 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New shot cuts swelling attacks in rare disease over long term
Disease control CompletedThis study tested a drug called garadacimab (CSL312) for long-term prevention of hereditary angioedema (HAE) attacks, which cause painful swelling. 171 people aged 12 and older received regular injections. The goal was to see if the drug is safe and reduces attack frequency over …
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New pill could stop painful swelling attacks in their tracks
Symptom relief CompletedThis study tested an oral medication called deucrictibant for quickly relieving attacks of hereditary angioedema (HAE), a condition causing sudden, painful swelling. 134 people aged 12 to 75 took the drug or a placebo when an attack started. The goal was to see if the pill speeds…
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Symptom relief
Last updated May 15, 2026 11:55 UTC
-
New pill could stop painful swelling attacks in rare disease
Symptom relief CompletedThis study tested an oral medication called deucrictibant for quickly relieving symptoms of hereditary angioedema (HAE) attacks, such as skin swelling, skin pain, and belly pain. 74 adults with HAE types I or II took either one of three doses of the drug or a placebo during an at…
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE2 • Sponsor: Pharvaris Netherlands B.V. • Aim: Symptom relief
Last updated Apr 30, 2026 15:50 UTC
-
Real-World data on HAE attack treatment collected in completed study
Knowledge-focused CompletedThis study followed 88 people with hereditary angioedema (HAE) types I or II who already use icatibant for sudden attacks. Participants filled out diaries for 48 hours after each attack to report symptom changes and anxiety levels. The goal was to understand how well icatibant wo…
Matched conditions: HEREDITARY ANGIOEDEMA
Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Knowledge-focused
Last updated May 17, 2026 06:49 UTC